Arvinas, Inc. (ARVN)
$6.84-8.19%Close
SELLCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $441M
- Beta
- 1.81
- P/E (TTM)
- 36.00
- Short % float
- 9.65%
- Days to cover
- 6.6
- SI change
- +8.1%
- 1W
- -6.43%
- 1M
- -18.57%
- vs SPY 1W
- -6.29%
- vs SPY 1M
- -21.08%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 13
- VALUE
- 6
- GROWTH
- 57
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC1.1%
REV YoY-
ROE1.9%
EPS YoY-
ROA1.4%
GROSS96
OP-4
NET3
[VALUATION]
P/E TTM36.00
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B0.79
P/FCF-
EV/EBITDA91.08
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E1.46
ALTMAN Z-
CURR RATIO7.91
ND/EBITDA-
BETA1.81
Company news
FAQ
- What is LOPJLB’s current signal on ARVN?
- LOPJLB’s latest quantitative signal on Arvinas, Inc. (ARVN) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ARVN in?
- Arvinas, Inc. (ARVN) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Arvinas, Inc. (ARVN) do?
- Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which s…